NASDAQ OMX

Deloitte Digital is Named the CloudCraze 2017 Global Partner of the Year

Dela

Deloitte Digital recognized in CloudCraze's first annual partner awards for contributions to joint client wins, team enablement and implementation success

CHICAGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- CloudCraze, the B2B commerce platform built natively on Salesforce, is pleased to honor Deloitte Digitalwith its 2017 Global Partner of the Year award. Deloitte Digital was chosen for its deep commitment to the alliance resulting in significant client wins, a large fully-enabled team and successful customer implementations. With its strong B2B commerce experience Deloitte has created CloudCraze solutions for customers that increase revenue, easily adapt to market changes and scale for growth.

For its inaugural awards, CloudCraze assessed partners' achievements in sales collaboration, co-marketing, client wins, consultant enablement, and service delivery excellence. Deloitte Digital has shown exceptional performance supporting joint customers by getting the CloudCraze solution to market quickly, developing products for unique enterprise needs in manufacturing and consumer goods, maximizing customers' investments in Salesforce.

"We are thrilled to present our Platinum Partner, Deloitte Digital, with our first-ever Global Partner of the Year award," said Ray Grady, CCO and President of CloudCraze. "As more brands have recognized the power of B2B commerce on Salesforce, CloudCraze has extended its partner network within the Salesforce ecosystem to provide increased scalability and robust professional services. Deloitte Digital has been an indispensable partner in the success of a number of our global customers."

Since the inception of Deloitte Digital's formal alliance with CloudCraze in 2016, the team has played a critical role in the development and implementation of leading B2B commerce solutions in the cloud. Together, CloudCraze and Deloitte Digital offer joint customers a unified customer experience across the digital enterprise, integrating digital cloud platforms such as CRM, commerce, marketing and other engagement channels for a holistic customer view and increased sales.

"We deeply value our relationship with CloudCraze and are honored to be recognized with this award," said Deloitte Digital's Paul do Forno, managing director, Deloitte Consulting LLP. "With the B2B commerce industry expected to reach $1 trillion by 2020, we're empowering enterprises to capitalize on this market growth through scalable and flexible SaaS solutions. We look forward to a bright future with CloudCraze serving some of the world's most iconic brands."

For more information on CloudCraze's alliance with Deloitte Digital, click here.

About CloudCraze
CloudCraze delivers robust B2B commerce native on Salesforce. It allows businesses to generate online revenue fast and easily scale for growth. Its Customer-First Commerce model puts the customer at the core, informing every interaction with data across commerce, sales, marketing, service and more. With the trusted Salesforce infrastructure and core capabilities, CloudCraze provides infinite flexibility to extend functionality, add products and channels, and conduct billions of dollars in transactions anywhere. CloudCraze powers Customer-First Commerce for industry leaders such as AB InBev, Coca-Cola, Ecolab, GE, Hallmark, Kaplan, Kellogg's Land O'Lakes, L'Oreal, Symantec, Tyco.
 
CloudCraze is funded by Insight Venture Partners and Salesforce Ventures. CloudCraze is recognized as a Visionary in the Gartner Magic Quadrant for Digital Commerce 2017, and a Strong Performer in The Forrester Wave: B2B Commerce Suites, Q1 2017 and The Forrester Wave: B2B Commerce Suites for Midsize Organizations, Q3 2017. CloudCraze is a Salesforce Platinum ISV Partner.

About Deloitte
Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world's most admired brands, including more than 85 percent of the Fortune 500 and more than 6,000 private and middle market companies. Our people work across more than 20 industry sectors to make an impact that matters - delivering measurable and lasting results that help reinforce public trust in our capital markets, inspire clients to see challenges as opportunities  to transform and thrive, and help lead the way toward a stronger economy and a healthy society. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. 

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

Media contacts
Sarah Traxler
Senior Director, Marketing
sarah.traxler@cloudcraze.com
866.217.3210




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CloudCraze via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress13.8.2018 08:00Pressmeddelande

Pressmeddelande 13 augusti 2018 Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress Immunicum AB (publ; IMMU.ST) tillkännagav idag att bolaget kommer att presentera en poster om sin ledande produktkandidat, ilixadencel, på 2018 års kongress för European Society for Medical Oncology (ESMO) , som hålls den 19-23 oktober 2018 i München i Tyskland. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande som följer efter presentationen. En sammanfattning av postern kommer också att publiceras i ESMO 2018 Congress Abstract Book, ett komplement till ESMO:s officiella årsbok, Annals of Oncology. Posterinformation: Titel: Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect (Intratumoral administration av pro-inflammatoriska allogena dendritiska celler som kan lagr

Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress13.8.2018 08:00Pressmeddelande

Press Release 13 August 2018 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress Immunicum AB (publ; IMMU.ST) announced today that the company will present a poster on its lead development candidate, ilixadencel, at the European Society for Medical Oncology (ESMO) 2018 Congress, held October 19-23, 2018 in Munich, Germany. Immunicum will announce the complete data through a press release following the presentation. The poster abstract will also be published in the ESMO 2018 Congress Abstract Book, a supplement to the official ESMO journal, Annals of Oncology. Poster Information: Title: Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect Presentation Number: 440P Presenter: Dr. Alex Karlsson-Parra, Chief Scientific Officer Date & Time: Monday, October 22, 2018; 12.45 - 13.45 CET Location: H

Corline Biomedical AB: Läkemedelsverket ger tillstånd till klinisk prövning av Renaparin®6.8.2018 15:29Pressmeddelande

Corline Biomedical AB ("Corline") har i beslutsbrev från Läkemedelsverket erhållit tillstånd att genomföra klinisk prövning av läkemedelskandidaten Renaparin®. Läkemedelsverkets tillståndsmeddelande innebär att samtliga formella krav är uppfyllda för genomförande av studien RENAPAIR 01, som är en säkerhetsstudie i fas 1 omfattande totalt 18 patienter. Renaparin® är under utveckling för att förbättra njurtransplantation och administreras till njuren före transplantation i syfte att minska njurskador som annars kan uppstå då den mottagande patientens blodflöde kopplas ihop med donator-njuren. Corline meddelade i juni 2018 att man till Läkemedelsverket inlämnat ansökan om att få genomföra klinisk prövning av Renaparin® i en placebo-kontrollerad studie (RENAPAIR 01, Eudra-CT 2017-002075-25) där 9 patienter transplanteras med njurar som erhållit aktiv substans och 9 patienter får overksam placebo. Denna ansökan har nu godkänts av Läkemedelsverket. Studien inleds i Uppsala och genomförs däre

Cisco Schedules Conference Call for Q4 and Fiscal Year 2018 Financial Results1.8.2018 22:30Pressmeddelande

SAN JOSE, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Cisco has scheduled a conference call for Wednesday, August 15, 2018, at 1:30 PM (PT); 4:30 PM (ET) to announce its fourth quarter and fiscal year 2018 financial results for the period ending Saturday, July 28, 2018. Financial results will be released over GlobeNewswire via US National, European Technology Trade Media and Western Europe distribution circuits, after the close of the market on Wednesday, August 15, 2018. Cisco's quarterly earnings press release will be posted at www.cisco.com under the "Newsroom" section. Date: Wednesday, August 15, 2018 Time: 1:30 PM (PT); 4:30 PM (ET) To Listen via Telephone: 888-848-6507 212-519-0847 (for International Callers) RSVP: No RSVP is necessary To Listen via the Internet: We are pleased to offer a live and replay audio broadcast of the conference call with corresponding slides at https://investor.cisco.com. Replay: A telephone playback of the Q4 and FY2018 conference call is scheduled to be

Corline Biomedical AB: Corline erhåller andra utbetalningen från EU-kommissionen31.7.2018 08:45Pressmeddelande

Corline Biomedical AB ("Corline") meddelade i november 2016 att EU-kommissionen beslutat anslå ca 2,4 MEUR (ca 23,1 MSEK) till bolagets kliniska studie inom njurtransplantation med läkemedelskandidaten Renaparin ® . En första utbetalning från H2020-programmet till Corline om ca 1,2 MEUR genomfördes i mars 2017. Corline har nu sammanställt en rapport till EU-kommissionen i vilken framgår att samtliga delmål i projektets första fas är uppnådda. Därmed har kommissionen beslutat om fortsatt stöd och en andra delbetalning om ca 1 MEUR utbetalas inom kort. Corline erhåller anslaget för att genomföra den planerade kliniska fas 1-studien för Renaparin® som är under utveckling för att förbättra njurtransplantation. Den första projektfasen har bland annat innefattat GMP-produktion av läkemedelssubstansen och upprättande av ansökan om klinisk prövning samt inlämnande av densamma till Läkemedelsverket. Samtliga delmål i den första projektfasen har uppfyllts och rapporteringen om dessa har nu grans

RFA Accelerates Growth with Expansion in Luxembourg30.7.2018 15:00Pressmeddelande

RFA announces new private financial cloud in Luxembourg to accelerate growth and accommodate increased demand in technology regulation and cybersecurity LUXEMBOURG, July 30, 2018 (GLOBE NEWSWIRE) -- RFA, a next-gen managed IT service provider for the financial industry, announces a new private financial cloud in Luxembourg. This expansion allows RFA to accommodate accelerated growth in Europe and offer a portfolio of high quality private cloud services to both its existing and new financial services clients in Luxembourg, Madrid, Paris, and the wider region. Along with the London office, the new office doubles RFA's footprint in Europe and further bolsters the company's growth strategy. RFA has two highly secure, tier-one data centres in Luxembourg which meet the ISO27001 and SSAE16/Type II standards, which is key for firms regulated by the Commission de Surveillance du Sector Financier (CSSF). RFA is now ideally placed to provide a range of services to clients in this region, and offe

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum